| Literature DB >> 32435379 |
Jesus M Ontoria1, Ilaria Biancofiore1, Paola Fezzardi1, Federica Ferrigno1, Esther Torrente1, Stefania Colarusso1, Elisabetta Bianchi1, Matteo Andreini1, Alexandros Patsilinakos1, Georg Kempf2, Martin Augustin2, Stefan Steinbacher2, Vincenzo Summa1, Robert Pacifici3, Ignacio Muñoz-Sanjuan3, Larry Park3, Alberto Bresciani1, Celia Dominguez3, Leticia Toledo Sherman3, Steven Harper1.
Abstract
The NRF2-ARE pathway is an intrinsic mechanism of defense against oxidative stress. Inhibition of the interaction between NRF2 and its main negative regulator KEAP1 is an attractive strategy toward neuroprotective agents. We report here the identification of nonacidic tetrahydroisoquinolines (THIQs) that inhibit the KEAP1/NRF2 protein-protein interaction. Peptide SAR at one residue is utilized as a tool to probe structural changes within a specific pocket of the KEAP1 binding site. We used structural information from peptide screening at the P2 pocket, noncovalent small-molecules inhibitors, and the outcome from an explorative SAR at position 5 of THIQs to identify a series of neutral THIQ analogs that bind to KEAP1 in the low micromolar range. These analogs establish new H-bond interactions at the P3 and P2 pockets allowing the replacement of the carboxylic acid functionality by a neutral primary carboxamide. X-ray crystallographic studies reveal the novel binding mode of these molecules to KEAP1.Entities:
Year: 2020 PMID: 32435379 PMCID: PMC7236277 DOI: 10.1021/acsmedchemlett.9b00594
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345